Know Cancer

forgot password

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Phase 1
18 Years
Open (Enrolling)
Advanced Solid Tumors, Lymphomas

Thank you

Trial Information

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Inclusion Criteria:

1. Subjects with histological or cytological confirmation of advanced cancer that is
refractory to standard therapies for their condition.

2. Men and women of ≥18 years of age.

3. ECOG performance score ≤2.

4. Eligible subjects MUST have at least one measurable lesion as defined by RECIST
guidelines. If the measurable disease is restricted to a solitary lesion, its
neoplastic nature should be confirmed by cytology/histology. Measurable lesions MUST
NOT have been in a previously irradiated field or injected with biological agents.
Eligible subjects with lymphomas must have measurable disease as defined by the
revised International Working Group response criteria.

5. Life expectancy ≥12 weeks.

6. Adequate bone marrow, liver and renal function as assessed by the following
laboratory requirements, to be conducted <2 weeks prior to Baseline:

- Creatinine ≤1.5 × upper limit of normal (ULN) OR a calculated creatinine
clearance ≥50 cc/min

- Total bilirubin ≤2 × ULN

- Alanine transaminase (ALT) and aspartate transaminase (AST) ≤3 × ULN

- Granulocytes in peripheral blood ≥1 × 109/L, hemoglobin ≥10 g/dL, and platelets
≥50,000 /μL

7. Adequate vascular access for repeated blood sampling.

8. Men and women of childbearing potential must agree to use effective contraception
from Screening through the duration of Study participation.

9. Written informed consent in compliance with ZIOPHARM policies and the Human
Investigation Review Committee (IEC/IRB) having jurisdiction over the site.

Exclusion Criteria:

1. New York Heart Association (NYHA) functional class ≥3 myocardial infarction within 6

2. Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation; a QTc
≥450 msec; or a ≥Grade 2 atrioventricular (AV) block or left bundle branch block
(LBBB); or documented history of prolonged QTc.

3. Pregnant and/or lactating women.

4. Uncontrolled systemic infection (documented with microbiological studies).

5. Metastatic brain or meningeal tumors.

6. Subjects with seizure disorder requiring medication (such as anti-epileptics).

7. History of confusion or dementia or neurological condition that could mask a
potential adverse response to the Study Drug, which may include transient ischemic
attack, Parkinson's disease, thrombotic or hemorrhagic stroke, Alzheimers, and other
neurological disorders.

8. Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of Study
entry (mitomycin C or nitrosureas should not be given within 6 weeks of Study entry).

9. Radiotherapy during study or within 3 weeks of Study entry.

10. Surgery within 4 weeks of start of Study Drug dosing.

11. Investigational drug therapy outside of this trial during or within 4 weeks of Study

12. History of invasive second primary malignancy diagnosed within the previous 3 years
except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated
surgically, and non-melanoma skin cancer.

13. Substance abuse, medical, psychological, or social conditions that may interfere with
the subject's participation in the study or evaluation of Study results.

14. Any condition that is unstable or could jeopardize the safety of the subject and
his/her compliance in the Study.

15. Arsenic allergy.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:


Outcome Time Frame:

6 months

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

December 2007

Completion Date:

June 2013

Related Keywords:

  • Advanced Solid Tumors
  • Lymphomas
  • Cancer
  • Arsenic
  • Lymphoma
  • Neoplasms